tiprankstipranks
Trending News
More News >

Esperion signs settlement with Accord Healthcare over Nexletol generic version

Esperion (ESPR) has entered into a settlement agreement with Accord Healthcare. This agreement resolves the patent litigation brought by Esperion against Accord Healthcare in response to Accord Healthcare’s Abbreviated New Drug Application seeking approval to market a generic version of Nexletol prior to the expiration of the applicable patents. Accord Healthcare has agreed not to market a generic version of Nexletol in the U.S. prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants – Alkem Laboratories; Aurobindo Pharma; Dr. Reddy’s Laboratories; MSN Pharmaceuticals; Renata Limited; and Sandoz – is ongoing.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1